Crizotinib and Early-Stage ALK Lung Cancer Survival
Here’s a breakdown of the ALCHEMIST clinical trial based on the provided text:
What was studied?
The ALCHEMIST trial investigated whether adding crizotinib (an ALK inhibitor) to standard post-surgical care would improve outcomes for patients with resected (surgically removed) Stage IIA-IIIB ALK-positive Non-Small Cell Lung Cancer (NSCLC).
Who was studied?
166 patients with resected Stage IIA-IIIB ALK+ NSCLC (confirmed by testing).
Patients had clean surgical margins and good overall health (ECOG performance status 0-1).
Patients had not previously received ALK inhibitor therapy.
Adjuvant chemotherapy and radiation were allowed.
What did the researchers do?
Patients were randomly assigned to one of two groups:
Observation: standard monitoring after surgery.
Crizotinib: Received crizotinib 250mg twice daily for up to two years, or until the cancer returned or side effects were unacceptable.
What were the results?
Disease-Free Survival (DFS): No meaningful difference. Median DFS was similar in both groups (72.8 months with crizotinib vs. 75.1 months with observation).
Overall Survival (OS): No significant difference. Median OS was not reached in either group, but showed a trend towards benefit with crizotinib (HR 0.49).
Side Effects: Crizotinib caused significant side effects:
34% experienced Grade 3 (serious) treatment-related events.
Common side effects included diarrhea (6%) and edema (4%).
One patient had a Grade 4 event (stroke).
22% needed dose reductions, and 25% stopped treatment due to side effects.
What was concluded?
Adjuvant crizotinib does not* improve disease-free survival in patients with resected ALK+ NSCLC.
Importent Note: The trial was stopped early after alectinib (another ALK inhibitor) was approved for this same patient population.